Professor of Pharmacology and Medical Specialist
at University of Extremadura and Badajoz University Hospital
Adrián Llerena is the Director of Extremadura Biosanitary Research Institute and the Clinical Research Center at the University Hospital of Badajoz. He is also Professor of Pharmacology and Clinical Pharmacology in the Medical School of the University of Extremadura. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his postdoc at the Karolinska Institute, focusing on clinical pharmacogenetics. He has nearly 40 years of teaching experience, has published more than 200 peer-reviewed papers and book chapters and has supervised over 25 PhD theses. He has also been an invited as Professor in different Universities in USA such as University of California at Los Angeles 2004 Mount Sinai Medical School at NY 2005 and Miller Medical School at Miami 2006 and in Latin America such as UNAM in Mexico San Marcos in Peru Chile Brazil etc. He is also coordinating the RIBEF Ibero-American network of Pharmacogenetics since 2006. He served in different Scientific societies as Ibero-American Society of Pharmacogenomics. He has been Principal Investigator in more than 25 national and European research projects. He has also served as reviewer in all journals related to clinical pharmacology and mainly pharmacogenetics and clinical psychopharmacology. Former Vice-president of the Spanish Society of Clinicial Pharmacology and President of the Spanish Society for Pharmacogenetics and Pharmacogenomics (2019-23). Currently is the coordinator of the IMPaCT WP05-Pharmacogenenetics Implementation in Spain and Pharmacogenetics MedeA Clinical Implementation in Extremadura Health System. He is also the coordinator of the Committee of Pharmacogenomics in the Spanish Ministry of Health Portafolio, and advisor of the Spanish Drug Regulatory Agency Database. Member of EMA-Pharmacogenomic Parthy (now ESEC-MWP) since 2010. Advisor of WHO/PAHO, CIOMS and several international organizations.
Accreditations
Publication- Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations
Publication- A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
Publication- Pharmacogenomic information in drug labels: European Medicines Agency perspective.
Publication- Population Pharmacogenetics in Ibero Latinoamerican Populations MESTIFAR
Areas of Expertise
Got a Question for Adrian Llerena?
Get in touch using the contact form linked here and we’ll get back to you shortly.